Orexo
Tracked across 2 events · 15 articles · First seen Mar 06, 2026 · Last active Mar 06, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Orexo is undergoing organizational and management changes following the divestment of Orexo===Buprenorphine/naloxone in the US market. These changes aim to sharpen its focus on advancing its pipeline, unlocking the potential of Orexo===AmorphOX technology, and building strategic partnerships.
Mar 06, 2026 · 8 articles
Business
Orexo is hosting an R&D Day to outline its updated strategy and R&D priorities, focusing on its Orexo===AmorphOX technology and pipeline products Orexo===OX640 and Orexo===OX390. This event is expected to provide clarity on the company's future direction and potential growth areas.
Mar 06, 2026 · 7 articles
Orexo===AmorphOX
developer of
↔
Orexo
Orexo is the developer of the proprietary drug delivery technology Orexo===Amorp
Orexo===Buprenorphine/naloxone
divested product
↔
Orexo
Orexo===Buprenorphine/naloxone was a product of Orexo that has been divested in
Orexo===OX640
developer of
↔
Orexo
Orexo is developing Orexo===OX640, a powder-based intranasal epinephrine product
Lisa Moore
Senior Vice President, Products and Portfolio Strategy
↔
Orexo
Lisa Moore is the Senior Vice President, Products and Portfolio Strategy at Orex
Robert DeLuca
former President of <<>> US Inc.
↔
Orexo
Robert DeLuca was the President of Orexo US Inc. and will now serve in an adviso
Orexo===OX390
developer of
↔
Orexo
Orexo is developing Orexo===OX390, a powder-based intranasal rescue medication c
NEWSDESK
Track Orexo live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard